- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2019–2024 · cooperative agreement · U24
Developing Informatics Technologies to Model Cancer Gene Regulation
Xiaole Shirley Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · career development · K22
Noninvasive monitoring and evaluation of anti-tumor responses as a predictive tool
Mohammad Rashidian · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2028 · research · R01
Development and vascularity of intestinal mesenchyme
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · fellowship · F32
Elucidating the role of the SAGA complex in MYCN-amplified neuroblastoma
Clare Felicity Malone · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2020 · fellowship · Postdoctoral Fellowship
Functional and mechanistic studies of a mitochondrial phosphocreatine phosphatase in beige adipocytes
Yizhi Sun · Dana-Farber Cancer Institute · funded by American Heart Association
2019–2021 · research · R01
Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy
Wilfred Ngwa · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019 · award · grant
High-Intensity Interval Training to Improve Cognitive Function in Breast Cancer Survivors Undergoing Chemotherapy
Dana-Farber Cancer Institute · funded by American Institute for Cancer Research
2019–2026 · cooperative agreement · UG1
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
Harold John Burstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Novel Screening Platform for Discovery of DUB Targeting Probes
Sara J Buhrlage · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2020 · fellowship · F32
Molecular tumor subtypes and prostate cancer disparities
Kevin Hughes Kensler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Genetic dissection of neural pathways that modulate systemic inflammation
Qiufu Ma · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Small molecules targeting hepatic glucose production and insulin resistance
Patrick Robert Griffin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R50
Functions of Cyclin/CDK complexes in development and cancer
Yan Geng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · career development · K99
Structure and Function of ATP-Dependent Chromatin Remodeling Complexes in Human Cancer
Nazar Mashtalir · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2021 · research · R21
The role of Ig Polymorphism in shaping the Broadly Neutralizing Antibody Response to Hemagglutinin HA stem domain(s) of Influenza A, Group 1 and 2 Viruses
Wayne A. Marasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
CDC7 kinase in normal and cancer cells: potential implications for cancer treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Understanding and addressing sub-optimal responses to CAR T cell therapy for Multiple Myeloma
Eric L Smith · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · research · R01
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R21
Passive Data to Improve Outcomes in Advanced Cancer
Jukka-Pekka Onnela · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Informed Combination Strategies for Peripheral T-cell Lymphomas
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · research · R35
Deciphering the mechanism underlying BRCA1 breast cancer development
David Morse Livingston · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Informed Combination Strategies for Peripheral T-cell Lymphomas
David Marc Weinstock · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · training · T32
Cancer Chemical Biology and Metabolism Training Program
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R01
Control of PGC1alpha Translation and Function
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · research · R35
Deciphering the mechanism underlying BRCA1 breast cancer development
David Morse Livingston · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R50
Functions of Cyclin/CDK complexes in development and cancer
Yan Geng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · training · T32
Cancer Chemical Biology and Metabolism Training Program
Nika N Danial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2026 · grant · BCRP
Prospectively Randomized, Placebo-Controlled Phase 3 Study to Determine the Effect of Denosumab on Breast Cancer Prevention in BRCA1 Mutation Carriers
Judy Garber · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2019–2025 · career development · K08
Expectations for Pediatric Cancer Treatment (EXPECT): A Family-Centered Intervention to Prepare Parents for Pediatric Leukemia Therapy
Katie A. Greenzang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Integration of early genetic alterations and inflammation in gastroesophageal premalignancy
Nilay Sethi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · career development · K00
Cancer Therapeutic Resistance: Implication of AcAPE1 Mediated DNA Repair and T-Cell Based Immunotherapy
Shrabasti Roychoudhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · career development · K08
Integration of early genetic alterations and inflammation in gastroesophageal premalignancy
Nilay Sethi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
CDC7 kinase in normal and cancer cells: potential implications for cancer treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · research · R01
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2022 · research · R01
Genetic dissection of neural pathways that modulate systemic inflammation
Qiufu Ma · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2023 · career development · K00
Cancer Therapeutic Resistance: Implication of AcAPE1 Mediated DNA Repair and T-Cell Based Immunotherapy
Shrabasti Roychoudhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2020 · fellowship · Postdoctoral Fellowship
Therapeutic targeting of SREBP-dependent lipogenesis by disrupting essential protein-protein interactions
Andras Boeszoermenyi · Dana-Farber Cancer Institute · funded by American Heart Association
2019–2023 · research · R01
Cellular and molecular characterization of the digestive tract sub-epithelium
Ramesh A Shivdasani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · cooperative agreement · U01
The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
